Compare Gilead Sciences, Inc. (GILD) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Gilead Sciences, Inc. trades at $134.68 (market cap $163.51B), while YieldMax TSLA Option Income Strategy ETF trades at $26.14. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while YieldMax TSLA Option Income Strategy ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| GILD | TSLY | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $155.80 | $48.25 |
52-Week Low | $108.22 | $26.16 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
TSLY trades at $26.48, down 1.3% over the past day, with a bearish technical signal from moving averages and neutral oscillators. The ETF maintains a high distribution yield, with recent weekly dividends ranging from $0.26 to $0.52. Recent news highlights consistent distribution announcements from YieldMax, though coverage notes the fund's capped upside and volatility risks tied to its synthetic TSLA exposure.
The outlook for TSLY hinges on its ability to sustain high yields through option income strategies, but faces risks from Tesla's stock volatility and potential capital erosion. Investors should weigh the attractive income against significant downside exposure and limited growth potential in a bearish technical environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
